Private Litigators Will Pick Up FSMA Enforcement Where FDA Leaves Off
This article was originally published in The Tan Sheet
FDA’s Fabricant says the agency will use new enforcement tools under FSMA more to ensure food safety compliance. But a defense attorney notes the agency’s restricted resources likely will confine its action to high-profile cases. He adds private litigators are poised to compel compliance by threatening to pick up FSMA enforcement where the agency leaves off.
You may also be interested in...
Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.